The report of Global Arthritis Therapeutic market by and Region (Asia Pacific, North America, Europe, Latin America, and Middle East Africa) is expected to reach US$ 2.02 Bn by 2026, at a CAGR of XX% during a forecast period.
Arthritis treatment focuses on relieving pain and improving joint. The most common arthritis conditions are psoriatic arthritis, rheumatoid arthritis, osteoarthritis and others. The factors like increasing the geriatric population, the launch of novel therapeutic agents, and favorable reimbursement policies for high cost treatment fueling the growth of the global arthritis therapeutics market.
TNF inhibitors segment is expected to grow at the highest XX% CAGR during the forecast period.
In terms of drug class, the tumor necrosis factor (TNF) inhibitors segment is likely to account for a major share of the global arthritis therapeutics market. TNF inhibitors include Enbrel, Humira, Remicade (infliximab), Simponi (golimumab), and Cimzia (certolizumab pegol) are preferred over other drugs, and are used in the development of novel therapeutic products for arthritis treatment. The patent of the blockbuster drug Humira is expiring in the 2020s. TNF inhibitor is applicable for rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, ulcerative colitis, and Crohn’s disease. Therefore, TNF inhibitors segment is expected to grow at the highest XX% CAGR during the forecast period.
The Asia Pacific dominated the Global Arthritis Therapeutic Market in 2018
North America dominated the global arthritis therapeutics market, followed by Europe. Because of a large patient pool suffering from arthritis diseases like osteoarthritis, rheumatoid arthritis and other conditions. Advantageous reimbursement policies, launching of novel biologics drugs, well-defined regulatory framework, and availability of biosimilars are boost up the market growth in the region. Moreover, the presence of key players in the region and a strong product pipeline for arthritis treatment are projected to drive the arthritis therapeutics market in the region.
Key players operating the Global Arthritis Therapeutic market are Pfizer Inc., Bristol Myers Squibb, Abbvie Inc., Astrazeneca Pharma, Ucb Pharma, Genentech, Janssen Pharmaceutical, Immunex Corp., Medac Pharma, Boehringer Ingelheim, Novartis, Biogen, Eli Lilly And Company, Astellas Pharma, Mallinckrodt, Roche, Vertex Pharmaceuticals and others.
Maximize Market Research, a global market research firm with a dedicated team of specialists and data has carried out extensive research about the Global Arthritis Therapeutic market. The report encompasses the market by different segments and region, providing an in-depth analysis of the overall industry ecosystem, useful for making an informed strategic decision by the key stakeholders in the industry. Importantly, the report delivers forecasts and share of the market, further giving an insight into the market dynamics, and future opportunities that might exist in the Global Arthritis Therapeutic market. The driving forces, as well as considerable restraints, have been explained in depth. in addition to this, competitive landscape describing the strategic growth of the competitors have been taken into consideration for enhancing market know-how of our clients and at the same time explain Global Arthritis Therapeutic market positioning of competitors.
Browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on “Global Arthritis Therapeutic Market”
https://www.maximizemarketresearch.com/market-report/global-arthritis-therapeutic-market/36112/
Contact:
MAXIMIZE MARKET RESEARCH PVT. LTD.
Omkar Heights,
ManikBaug, Vadgaon Bk,
Sinhagad Road, Pune – 411051, Maharashtra, India.
+91 9607195908